Stimulation of new bone formation by the proteasome inhibitor, bortezomib: Implications for myeloma bone disease

British Journal of Haematology

Volumn 139, Issue 3, 2007, Pages 434-438

  Oyajobi, Babatunde O ^a,b,d   Garrett, I Ross ^a,c   Gupta, Anjana ^a   Flores, Alda ^c   Esparza, Javier ^c   Muñoz, Steve ^a,e   Zhao, Ming ^a,e   Mundy, Gregory R ^a,b,d,e  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c OsteoScreen   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone; Bortezomib; Dkk1; Myeloma; Osteoblast

Indexed keywords

BORTEZOMIB; PROTEASOME INHIBITOR; PROTEIN DICKKOPF 1; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; BONE DISEASE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; MOUSE; MYELOMA; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DIFFERENTIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED ICR; ORGAN CULTURE TECHNIQUES; OSTEOBLASTS; OSTEOGENESIS; PROTEASE INHIBITORS; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKULL;

EID: 34848853850     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06829.x     Document Type: Article

References (15)

1. Bataille, R., Delmas, P.D., Chappard, D. Sany, J. (1990) Abnormal serum bone Gla protein levels in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer, 66, 167 172.
2. Bhat, B., Lam, H., Coleburn, V.E., Anisowicz, A., Allen, K.M., Yaworsky, P. Bex, F.J. 2004) Importance of human DKK1 C-terminal 21 amino acids and glycosylation for its function as an antagonist of LRP5/6-Wnt-TCF signaling. Journal of Bone and Mineral Research, 19 (Suppl. S79.
3. Dhodapkar, M.V., Weinstein, R., Tricot, G., Jagannath, S., Parfitt, A.M., Manolagas, S.C. Barlogie, B. (1998) Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leukemia & Lymphoma, 32, 121 127.
4. Garrett, I.R. (2003) Assessing bone formation using mouse calvarial organ cultures. Methods in Molecular Medicine, 80, 183 198.
5. Garrett, I.R., Chen, D., Gutierrez, G., Zhao, M., Escobedo, A., Rossini, G., Harris, S.E., Gallwitz, W., Kim, K.B., Hu, S., Crews, C.M. Mundy, G.R. (2003) Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. Journal of Clinical Investigation, 111, 1771 1782.
6. Gonzalez-Sancho, J.M., Aguilera, O., Garcia, J.M., Pendas-Franco, N., Pena, C., Cal, S., Garcia de Herreros, A., Bonilla, F. Munoz, A. (2005) The Wnt antagonist DICKKOPF-1 gene is a downstream target of β-catenin/TCF and is downregulated in human colon cancer. Oncogene, 24, 1098 1103.
7. Holmen, S.L., Zylstra, C.R., Mukherjee, A., Sigler, R.E., Faugere, M.C., Bouxsein, M.L., Deng, L., Clemens, T.L. Williams, B.O. (2005) Essential role of β-catenin in postnatal bone acquisition. Journal of Biological Chemistry, 280, 21162 21168.
8. Richardson, P.G., Mitsiades, C., Hideshima, T. Anderson, K.C. (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annual Reviews in Medicine, 57, 33 47.
9. Stump, R.J., Ang, S., Chen, Y., von Bahr, T., Lovicu, F.J., Pinson, K., de Iongh, R.U., Yamaguchi, T.P., Sassoon, D.A. McAvoy, J.W. (2003) A role for Wnt/β-catenin signaling in lens epithelial differentiation. Developmental Biology, 259, 48 61.
10. Taube, T., Beneton, M.N., McCloskey, E.V., Rogers, S., Greaves, M. Kanis, J.A. (1992) Abnormal bone remodeling in patients with myelomatosis and normal biochemical indices of bone resorption. European Journal of Haematology, 49, 192 198.
11. Terpos, E., Heath, D.J., Rahemtulla, A., Zervas, K., Chantry, A., Anagnostopoulos, A., Pouli, A., Katodritou, E., Verrou, E., Vervessou, E.C., Dimopoulos, M.A. Croucher, P.I. (2006) Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. British Journal of Haematology, 135, 688 692.
12. Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B. Shaughnessy, J. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New England Journal of Medicine, 349, 2483 2494.
13. Withold, W., Schulte, U. Reinauer, H. (1996) Methods for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone disease. Clinical Chemistry, 42, 210 217.
14. Woitge, H.W., Horn, E., Keck, A.V., Auler, B., Seibel, M.J. Pecherstorfer, M. (2001) Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clinical Chemistry, 47, 686 693.
15. Zangari, M., Esseltine, D., Lee, C.K., Barlogie, B., Elice, F., Burns, M.J., Kang, S.H., Yaccoby, S., Najarian, K., Richardson, P., Sonneveld, P. Tricot, G. (2005) Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. British Journal of Haematology, 131, 71 73.